DSP 7888

Drug Profile

DSP 7888

Alternative Names: DSP-7888

Latest Information Update: 11 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Class Antineoplastics; Peptide vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Glioma; Myelodysplastic syndromes
  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 10 Jul 2017 DSP 7888 receives Orphan Drug status for Myelodysplastic syndromes in USA
  • 16 May 2017 Boston Biomedical plans a phase II trial for Glioblastoma (Combination therapy, Recurrent) (NCT03149003)
  • 11 May 2017 Phase-I clinical trials in Haematological malignancies (Monotherapy) in Canada (Intradermal) before May 2017 (Sumitomo Dainippon Pharma pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top